ANTIGEN EXCLUSIVITY Clause Samples

The Antigen Exclusivity clause establishes that one party has the exclusive right to use, develop, or commercialize a specific antigen or group of antigens within a defined field or territory. In practice, this means that the other party, and sometimes third parties, are restricted from engaging in activities involving the covered antigen(s) for the duration of the agreement. This clause is commonly used in biotechnology and pharmaceutical agreements to protect a party’s investment in research and development by preventing competitors from working with the same biological targets, thereby reducing the risk of market competition and ensuring a clear path to commercialization.
ANTIGEN EXCLUSIVITY. Subject to Sections 3.3.2 and 3.3.4, the Parties acknowledge and agree that this Collaboration shall be exclusive with respect to the Collaboration Targets and that no Party shall engage, directly or indirectly, on behalf of itself or any other party, in the research, development, commercialization or other Exploitation of antibody-based products with respect to any Collaboration Target other than the Collaboration Products and Unilateral Products as provided in this Agreement and any related agreements between the Parties.
View SourceView Similar (5)
ANTIGEN EXCLUSIVITY. Subject to Sections 2.2.2 and 2.2.4, the Parties acknowledge and agree that no Party shall engage, directly or indirectly, on behalf of itself or any other party, in the research, development, commercialization or other Exploitation of antibody-based products with respect to any Unilateral Target listed on Appendix A other than the Unilateral Products as provided to this Agreement.
View SourceView Similar (2)
ANTIGEN EXCLUSIVITY. (a) Subject to Sections 3.3.2, 3.3.3 and 3.3.4, the Parties acknowledge and agree that this Collaboration shall be exclusive with respect to the Collaboration Targets and that no Party shall engage, directly or indirectly, on behalf of itself or any other party, in the research, development, commercialization or other Exploitation of antibody-based prophylactic or therapeutic products with respect to any Collaboration Target other than the Collaboration Products and Unilateral Products as provided in this Agreement and any related agreements among the Parties. deCODE represents that it has entered into that certain Term Sheet re: Diagnostic Products between deCODE, a certain Third Party and Affiliates of such Third Party dated as of March 1, 2001, and any further agreement between deCODE, such Third Party and/or such Affiliates entered into pursuant thereto (the "PRE-EXISTING DIAGNOSTIC AGREEMENT"). deCODE acknowledges and agrees that it has no right to use, outside of the Collaboration, any Antibodies generated pursuant to this Agreement or a Unilateral Development and Commercialization Agreement, except as expressly set forth in the applicable Unilateral Development and Commercialization Agreement. (b) deCODE shall use commercially reasonable efforts (i) to develop and commercialize or cause to be developed and commercialized Diagnostic Products with respect to each Collaboration Target to the extent necessary or reasonably useful for the Exploitation of Collaboration Products with respect to such Collaboration Target, (ii) provide or cause to be provided such Diagnostic Products to the Collaborators at a commercially reasonable cost for use in connection with the development of such Collaboration Products, including to assist the Collaboration in selecting patients for clinical trials involving such Collaboration Products, and (iii) use commercially reasonable efforts, consistent with the Pre-Existing Diagnostic Agreement, to make such Diagnostic Products generally available to the public on commercially reasonable terms or cause to be so made to the extent necessary or reasonably useful to Exploit such Collaboration Products. (c) Notwithstanding clause (b) above, if at any time deCODE obtains rights, pursuant to the Pre-Existing Diagnostic Agreement or otherwise, to a Diagnostic Product with respect to a Collaboration Target, then deCODE shall offer such Diagnostic Product to Genmab/Medarex to be Exploited under the Collaboration as a Collaboration Pro...
View SourceView Similar (2)
ANTIGEN EXCLUSIVITY. (a) Subject to Sections 2.2.2, 2.2.3 and 2.2.4, the Parties acknowledge and agree that no Party shall engage, directly or indirectly, on behalf of itself or any other party, in the research, development, commercialization or other Exploitation of antibody-based prophylactic or therapeutic products with respect to any Unilateral Target listed on Appendix A other than the Unilateral Products as provided in this Agreement. deCODE represents that it has entered into that certain Term Sheet re: Diagnostic Products between deCODE, a certain Third Party and Affiliates of such Third Party dated as of March 1, 2001, and any further agreement between deCODE, such Third Party and/or such Affiliates entered into pursuant thereto (the "PRE-EXISTING DIAGNOSTIC AGREEMENT"). deCODE acknowledges and agrees that it has no right to use any Antibodies generated pursuant this Agreement or the Collaboration Agreement except as expressly set forth herein or therein. (b) deCODE shall use commercially reasonable efforts to (i) develop and commercialize or cause to be developed and commercialized Diagnostic Products with respect to each Unilateral Target to the extent necessary or reasonably useful for the Exploitation of Unilateral Products with respect to such Unilateral Target, and (ii) consistent with the Pre-Existing Diagnostic Agreement, make such Diagnostic Products generally available to the public on commercially reasonable terms or cause to be so made to the extent necessary or reasonably useful to Exploit such Unilateral Products.
View Source
ANTIGEN EXCLUSIVITY. Subject to Sections 3.3.2, 3.3.3 and 3.3.4, the Parties acknowledge and agree that no Party shall engage, directly or indirectly, on behalf of itself or with or through any other party, in the research, development, commercialization or other Exploitation of Antibody-Based Products with respect to the Collaboration Target, or grant any other right or license to do so, other than with respect to the Collaboration Products and Unilateral Products as provided in this Agreement and any related agreements between the Parties.
View Source

Related to ANTIGEN EXCLUSIVITY

  • Non-Exclusivity The services of the Adviser to the Manager, the Allocated Portion and the Trust are not to be deemed to be exclusive, and the Adviser shall be free to render investment advisory or other services to others and to engage in other activities. It is understood and agreed that the directors, officers, and employees of the Adviser are not prohibited from engaging in any other business activity or from rendering services to any other person, or from serving as partners, officers, directors, trustees, or employees of any other firm or corporation.

  • Non-exclusivity, Etc The rights of Indemnitee hereunder will be in addition to any other rights Indemnitee may have under the Charter, the Bylaws or the Maryland General Corporation Law (the "MGCL") or otherwise; provided, however, that to the extent that Indemnitee otherwise would have any greater right to indemnification under any provision of the Charter or Bylaws as in effect on the date hereof, Indemnitee will be deemed to have such greater right hereunder, and provided, further, that to the extent that any change is made to the MGCL (whether by legislative action or judicial decision), the Charter and/or the Bylaws which permits any greater right to indemnification than that provided under this Agreement as of the date hereof, Indemnitee will be deemed to have such greater right hereunder. The Company will not adopt any amendment to the Charter or the Bylaws the effect of which would be to deny, diminish or encumber Indenmitee's right to indemnification under the Charter, the Bylaws, the MGCL or otherwise as applied to any act or failure to act occurring in whole or in part prior to the date upon which the amendment was approved by the Company's Board of Directors and/or its stockholders, as the case may be.

  • No Exclusivity It is expressly understood and agreed by the parties that this is not an exclusive agreement. Nothing in this Agreement shall be construed as creating any exclusive arrangement with Contractor or as prohibit City from either acquiring similar, equal, or like goods and/or services or from executing additional contracts with other entities or sources.

  • Non-Exclusive License Sponsor grants Institution and Principal Investigator a royalty free non-exclusive license, with no right to sublicense, to use Trial Data for internal research or educational purposes.

  • Exclusivity Without prejudice to the Company’s rights under Section 5.4, the Company agrees not to appoint any other depositary for issuance of depositary shares, depositary receipts or any similar securities or instruments so long as The Bank of New York Mellon is acting as Depositary under this Deposit Agreement.